NASDAQ:GBT - Global Blood Therapeutics Stock Price, Forecast & News

$80.83

-1.24 (-1.51 %)

(As of 01/23/2020 03:29 AM ET)

Add

Compare

Today's Range

$80.35

Now: $80.83▼

$82.60

50-Day Range

$74.19

MA: $79.78▼

$87.16

52-Week Range

$43.69

Now: $80.83▼

$87.54

Volume922,644 shs

Average Volume1.01 million shs

Market Capitalization$4.87 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.75

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:GBT

Previous Symbol

CUSIPN/A

CIK1629137

Webhttp://www.gbt.com/

Phone650-741-7700

Debt

Debt-to-Equity Ratio0.04

Current Ratio14.95

Quick Ratio14.95

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$10.97 per share

Price / Book7.37

Profitability

EPS (Most Recent Fiscal Year)($3.41)

Net Income$-174,190,000.00

Net MarginsN/A

Return on Equity-35.32%

Return on Assets-32.27%

Miscellaneous

Employees171

Outstanding Shares60,231,000

Market Cap$4.87 billion

Next Earnings Date2/26/2020 (Estimated)

OptionableOptionable

Receive GBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.

(Ad)

If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics Inc (NASDAQ:GBT) issued its earnings results on Thursday, November, 7th. The company reported ($1.07) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.03) by $0.04. During the same period in the previous year, the business earned ($0.83) earnings per share. View Global Blood Therapeutics' Earnings History.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Global Blood Therapeutics.

What price target have analysts set for GBT?

16 Wall Street analysts have issued twelve-month target prices for Global Blood Therapeutics' shares. Their forecasts range from $50.00 to $150.00. On average, they anticipate Global Blood Therapeutics' stock price to reach $97.93 in the next year. This suggests a possible upside of 21.2% from the stock's current price. View Analyst Price Targets for Global Blood Therapeutics.

What is the consensus analysts' recommendation for Global Blood Therapeutics?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Global Blood Therapeutics.

What are Wall Street analysts saying about Global Blood Therapeutics stock?

Here are some recent quotes from research analysts about Global Blood Therapeutics stock:

1. HC Wainwright analysts commented, "Our Buy rating and $150 PT are based on a DCF analysis, derived using a beta of 1.58, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.8%, and tax rate of 15% beginning in FY 2024. We estimate approximately 70K patients in U.S., 42K patients in the $60K U.S. and EU launch prices, respectively, a 2020 commercial launch, 70% compliance, and 23% gross-to-net. In 2022, we model global sales at roughly $820M and expect voxelotor peak sales of $2.7B during 2026, which assumes about 49% adoption across the developed nations, and a POS of 75%." (8/8/2019)
2. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (3/4/2019)
3. William Blair analysts commented, "We continue to view the stock as substantially de-risked with the completion of 24 weeks of therapy in the additional 118 enrolled patients in the Phase III HOPE study , publication of the HOPE Part A data set, and a pre-NDA meeting update in the first half as well as potential Subpart H filing in the second half as key catalysts for shares this year . We also see the company as a potential takeout candidate given the significant unmet medical need in sickle cell disease, the impressive data shown in patients with or without concomitant hydroxyurea, and the alignment of a once-daily , oral therapy dosed (potentially) in perpetuity with the large pharma commercial model. GBT remains our top pick for 2019." (1/30/2019)

Has Global Blood Therapeutics been receiving favorable news coverage?

News headlines about GBT stock have trended very negative this week, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Global Blood Therapeutics earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Global Blood Therapeutics.

Who are some of Global Blood Therapeutics' key competitors?

Some companies that are related to Global Blood Therapeutics include UCB (UCBJF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Beigene (BGNE), Sarepta Therapeutics (SRPT), Ono Pharmaceutical (OPHLF) and Catalent (CTLT).

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Cynosure (CYNO), Exelixis (EXEL), TherapeuticsMD (TXMD), AbbVie (ABBV), Roku (ROKU), Sarepta Therapeutics (SRPT) and Advanced Micro Devices (AMD).

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the folowing people:

Dr. Ted W. Love, Pres, CEO & Director (Age 60)
Dr. Charles J. Homcy, Founder, Advisor & Director (Age 71)
Mr. Jeffrey S. Farrow, Chief Financial Officer (Age 57)
Mr. Peter Radovich, Sr. VP of Operations (Age 41)
Dr. Hing Sham, Sr. VP of Research (Age 67)

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an IPO on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Who are Global Blood Therapeutics' major shareholders?

Global Blood Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Profit Investment Management LLC (0.08%), Assenagon Asset Management S.A. (0.05%), Janney Montgomery Scott LLC (0.01%), Nisa Investment Advisors LLC (0.01%) and Wedbush Securities Inc. (0.01%). Company insiders that own Global Blood Therapeutics stock include De Dominicis Robert, Deval L Patrick, Joshua Lehrer-Graiwer, Jung Choi, Lesley Ann Calhoun, Peter Radovich, Philip A Pizzo, Ted W Love and Tricia Borga Suvari. View Institutional Ownership Trends for Global Blood Therapeutics.

Which major investors are selling Global Blood Therapeutics stock?

GBT stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC and Janney Montgomery Scott LLC. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Deval L Patrick, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Philip A Pizzo, Ted W Love and Tricia Borga Suvari. View Insider Buying and Selling for Global Blood Therapeutics.

Which major investors are buying Global Blood Therapeutics stock?

GBT stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Profit Investment Management LLC and Wedbush Securities Inc.. View Insider Buying and Selling for Global Blood Therapeutics.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $80.83.

How big of a company is Global Blood Therapeutics?

Global Blood Therapeutics has a market capitalization of $4.87 billion. The company earns $-174,190,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis. Global Blood Therapeutics employs 171 workers across the globe.View Additional Information About Global Blood Therapeutics.

What is Global Blood Therapeutics' official website?

The official website for Global Blood Therapeutics is http://www.gbt.com/.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]

MarketBeat Community Rating for Global Blood Therapeutics (NASDAQ GBT)

Community Ranking:		3.1 out of 5 ( )
Outperform Votes:		501 (Vote Outperform)
Underperform Votes:		310 (Vote Underperform)
Total Votes:		811

MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe GBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GBT will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: What is the FTSE 100 index?

Your Ultimate Investing Toolkit

Just $1.00 for your first month.